The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enrichment of allogeneic tumor antigen-specific T cells from bone marrow (BM) of patients treated with high-dose post-transplant cyclophoshamide (Cy): A novel approach to adoptive immunotherapy.
K. Noonan
No relevant relationships to disclose
L. Luznik
No relevant relationships to disclose
I. Borrello
No relevant relationships to disclose